Partner Irwin Raij was quoted in a September 16, 2013 Law360 article titled, “Fla. Puts New Spin On Public Stadium Financing.” The article discusses a new idea in public stadium financing coming from Orlando, Fla., where a county official is proposing that Orange County, Fla. be a full partner in bringing a proposed Major League Soccer team to town, contributing about $20 million toward the franchise fee and stadium — about a 13 percent stake, using total expected costs — and sharing in revenues. If the team is later sold or recapitalized, the county would get a split of the proceeds. Raij was quoted saying, “Equity owners get capital calls when there are problems. Everyone talks about what big business sports is and how everyone is just rolling in money, but there are huge risks.” Raij also noted that “There are better ways to protect the community interest without taking on equity risk. The end goal is, I think, a good one. You just have to think about how to get there, and that’s a local question that requires creativity.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”